subgroups, and taking current clinical practice into account The group conditionally discourages low (#7.5 mg/ day) and strongly recommends against high (.30 mg/day prednisone equivalent) initial GC doses. For this statement the group extrapolated the data from randomized controlled trials Recommendation 4: (PICO 6) The panel strongly recommends individualizing dose-tapering schedules, based on regular monitoring of patient disease activity, laboratory markers and adverse events. The following